20 December 2024
20 December 2024
MSD could pursue “cardiometabolic benefits beyond weight reduction” for Hansoh’s weight loss pill.
Once VPAG was introduced in early 2024, the initial headline payback value was only 15.1% for newer medicines in Q2–Q4.
Manufacturers of compounded versions of Mounjaro now have a deadline to halt production.
Vertex said the Phase II trial met its primary endpoint, however there was only a minor difference to placebo.
This is the only MSC therapy approved in the US for any indication.
Henlius has secured an exclusive licence to develop and commercialise E-602 in China.
Sangamo will obtain an upfront licence fee of $20m from Astellas.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
